SciClone Could Pay SEC $12.8 Million in FCPA Case
SciClone Pharmaceuticals has disclosed in a quarterly report that it’s discussing a tentative $12.8 million settlement with the Securities and Exchange Commission to resolve an investigation of potential violations of the Foreign Corrupt Practices Act with respect to its China operations. Details inside.
Related articles
-
News BriefDOJ declines to prosecute Liberty Mutual in $4.7M FCPA bribery case
Liberty Mutual agreed to give up $4.7 million in profit – the amount it earned from a bribery scheme uncovered by the government – as part of a settlement related to the Foreign Corrupt Practices Act, according to a letter from the U.S. Department of Justice.
-
ArticleDOJ, SEC end Investigations of GE HealthCare for possible FCPA violations in China
The Securities and Exchange Commission and Department of Justice ended a seven-year review of GE HealthCare Technologies’ China unit for possible violations of the Foreign Corrupt Practices Act.
-
WebcastAug 28 | White Collar Crime Enforcement Trends in Compliance in 2025
Join a fireside chat with Kenneth Polite Jr., partner at the law firm Sidley, who served as the Assistant Attorney General for the Criminal Division of the United States Department of Justice (DOJ) from 2021-23.